Polymorphism in the interleukin-17A promoter contributes to gastric cancer

作     者：Alireza Rafiei Vahid Hosseini Ghasem Janbabai Abuzar Ghorbani Abulghasem Ajami Touraj Farzmandfar Maedeh Darzyani Azizi Jeremy J Gilbreath D Scott Merrell 

作者机构：Molecular and Cell Biology Research CenterFaculty of MedicineMazandaran University of Medical Sciences Department of Internal MedicineImam Hospital Hematology and Oncology WardDepartment of Internal MedicineImam HospitalMazandaran University of Medical Sciences Department of Microbiology and ImmunologyUniformed Services University of the Health Sciences 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第34期

页      面：5693-5699页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by The Mazandaran University of Medical Sciences No.89-512 

主　　题：Gastric cancer Interleukin-17A Cancer Helicobacter pylori 

摘      要：AIM:To evaluate the contribution of the G-197A polymorphism in the interleukin-17(IL-17)promoter region to gastric cancer risk in an Iranian ***:We performed a case control study using samples from 161 individuals with gastric cancer and171 healthy *** each individual,the G-197A genotype was determined by restriction fragment length polymorphism analysis of polymerase chain reaction-amplified *** analyses were performed to determine whether any demographic or behavioral factors,infection with Helicobacter pylori(***),or a particular G-197A genotype was associated with gastric cancer ***:We found that the G-197A genotype wassignificantly associated with increased gastric cancer risk(P=0.001).Patients who were homozygous(AA)at position-197 were 2.9 times more likely to develop disease(95%CI:1.56-5.4;P=0.001).Furthermore,logistic regression analysis revealed that the presence of a single A allele increased the risk of gastric cancer up to 1.7-fold(95%CI:1.26-2.369;P=0.001).This association was observed for early stage gastric adenocarcinomas only,and was not linked to *** ***:These results suggest that carrying one or more G-197A polymorphisms at position-197 in the IL-17 promoter region significantly increases gastric cancer risk in this patient population.